Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.
Department of Pharmaceutical Sciences, Università degli Studi di Perugia, 06123 Perugia, Italy.
J Med Chem. 2024 Aug 8;67(15):13324-13348. doi: 10.1021/acs.jmedchem.4c01218. Epub 2024 Jul 30.
Nuclear receptor related 1 (Nurr1, NR4A2) is a ligand-sensing transcription factor with neuroprotective and anti-inflammatory roles widely distributed in the CNS. Pharmacological Nurr1 modulation is considered a promising experimental strategy in Parkinson's and Alzheimer's disease but target validation is incomplete. While significant progress has been made in Nurr1 agonist development, inverse agonists blocking the receptor's constitutive activity are lacking. Here we report comprehensive structure-activity relationship elucidation of oxaprozin which acts as moderately potent and nonselective inverse Nurr1 agonist and RXR agonist. We identified structural determinants selectively driving RXR agonism or inverse Nurr1 agonism of the scaffold enabling the development of selective inverse Nurr1 agonists with enhanced potency and strong efficacy.
核受体相关 1(Nurr1,NR4A2)是一种配体感应转录因子,具有神经保护和抗炎作用,广泛分布于中枢神经系统。药物调节 Nurr1 被认为是帕金森病和阿尔茨海默病的一种有前途的实验策略,但靶标验证并不完整。虽然在 Nurr1 激动剂的开发方面取得了重大进展,但缺乏阻断受体组成性活性的反向激动剂。在这里,我们报告了 oxaprozin 的全面构效关系研究,它是一种中等效力和非选择性的反向 Nurr1 激动剂和 RXR 激动剂。我们确定了结构决定因素,这些因素选择性地驱动了支架的 RXR 激动或反向 Nurr1 激动,从而能够开发出具有增强效力和强大疗效的选择性反向 Nurr1 激动剂。